0000899243-20-018817.txt : 20200709 0000899243-20-018817.hdr.sgml : 20200709 20200709161832 ACCESSION NUMBER: 0000899243-20-018817 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200708 FILED AS OF DATE: 20200709 DATE AS OF CHANGE: 20200709 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wallace Owen B. CENTRAL INDEX KEY: 0001778843 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38978 FILM NUMBER: 201020650 MAIL ADDRESS: STREET 1: C/O FULCRUM THERAPEUTICS, INC. STREET 2: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Fulcrum Therapeutics, Inc. CENTRAL INDEX KEY: 0001680581 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474839948 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-651-8851 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-08 0 0001680581 Fulcrum Therapeutics, Inc. FULC 0001778843 Wallace Owen B. C/O FULCRUM THERAPEUTICS, INC. 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Scientific Officer Common Stock 2020-07-08 4 M 0 2951 7.84 A 130039 D Common Stock 2020-07-08 4 S 0 2951 20.00 D 127088 D Stock Option (right to buy) 7.84 2020-07-08 4 M 0 2951 0.00 D 2029-01-21 Common Stock 2951 81942 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022. /s/ Peter Thomson, as attorney-in-fact for Owen B. Wallace 2020-07-09